Wells Trecaso Financial Group LLC lessened its stake in Thermo Fisher Scientific Inc. (NYSE: TMO – Get Rating) by 4.5% during the first quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 11,543 shares of the medical research company stock after selling 544 shares during the period. Thermo Fisher Scientific comprises about 3.0% of Wells Trecaso Financial Group LLC’s portfolio, making the stock its 9th biggest position. Wells Trecaso Financial Group LLC’s holdings in Thermo Fisher Scientific were worth $ 6,818,000 as of its most recent filing with the Securities and Exchange Commission.
Several other large investors have also recently bought and sold shares of the company. Norges Bank bought a new stake in shares of Thermo Fisher Scientific in the 4th quarter worth $ 2,784,029,000. BlackRock Inc. lifted its holdings in Thermo Fisher Scientific by 3.8% during the fourth quarter. BlackRock Inc. now owns 30,982,611 shares of the medical research company stock valued at $ 20,672,838,000 after purchasing an additional 1,143,333 shares during the last quarter. Marshall Wace LLP grew its stake in Thermo Fisher Scientific by 146.4% in the 4th quarter. Marshall Wace LLP now owns 1,043,844 shares of the medical research company stock valued at $ 696,497,000 after buying an additional 620,291 shares in the last quarter. Liontrust Investment Partners LLP bought a new stake in shares of Thermo Fisher Scientific during the 3rd quarter valued at $ 311,726,000. Finally, State Street Corp lifted its holdings in shares of Thermo Fisher Scientific by 3.4% in the fourth quarter. State Street Corp now owns 16,223,173 shares of the medical research company stock worth $ 10,828,875,000 after buying an additional 529,712 shares in the last quarter. 87.48% of the stock is currently owned by institutional investors.
Shares of TMO stock opened at $ 544.81 on Friday. The business has a fifty day simple moving average of $ 543.27 and a 200-day simple moving average of $ 574.11. The company has a quick ratio of 1.10, a current ratio of 1.56 and a debt-to-equity ratio of 0.77. The stock has a market cap of $ 213.27 billion, a P / E ratio of 28.41, a P / E / G ratio of 1.83 and a beta of 0.83. Thermo Fisher Scientific Inc. has a fifty-two week low of $ 491.18 and a fifty-two week high of $ 672.34.
Thermo Fisher Scientific (NYSE: TMO – Get Rating) last issued its quarterly earnings data on Thursday, April 28th. The medical research company reported $ 7.25 earnings per share for the quarter, beating analysts’ consensus estimates of $ 6.17 by $ 1.08. Thermo Fisher Scientific had a return on equity of 25.33% and a net margin of 18.49%. The firm had revenue of $ 11.82 billion during the quarter, compared to analyst estimates of $ 10.66 billion. During the same quarter last year, the firm earned $ 7.21 EPS. Thermo Fisher Scientific’s quarterly revenue was up 19.3% on a year-over-year basis. On average, sell-side analysts anticipate that Thermo Fisher Scientific Inc. will post 22.7 earnings per share for the current year.
The business also recently disclosed a quarterly dividend, which will be paid on Friday, July 15th. Investors of record on Wednesday, June 15th will be paid a $ 0.30 dividend. This represents a $ 1.20 dividend on an annualized basis and a dividend yield of 0.22%. The ex-dividend date of this dividend is Tuesday, June 14th. Thermo Fisher Scientific’s payout ratio is 6.26%.
TMO has been the subject of a number of research reports. StockNews.com began coverage on Thermo Fisher Scientific in a report on Thursday, March 31st. They issued a “hold” rating for the company. Wells Fargo & Company downgraded Thermo Fisher Scientific from an “equal weight” rating to an “underweight” rating and decreased their price objective for the stock from $ 605.00 to $ 525.00 in a report on Monday, April 25th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating, twelve have assigned a buy rating and one has given a strong buy rating to the company stock. According to MarketBeat.com, Thermo Fisher Scientific currently has a consensus rating of “Moderate Buy” and a consensus target price of $ 658.92.
In other news, Director Debora L. Spar sold 200 shares of the stock in a transaction on Monday, May 2nd. The stock was sold at an average price of $ 544.36, for a total transaction of $ 108,872.00. Following the sale, the director now directly owns 810 shares of the company stock, valued at approximately $ 440,931.60. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, CEO Marc N. Casper sold 10,000 shares of the business’s stock in a transaction dated Monday, May 2nd. The stock was sold at an average price of $ 545.60, for a total value of $ 5,456,000.00. Following the sale, the chief executive officer now owns 183,373 shares in the company, valued at $ 100,048,308.80. The disclosure for this sale can be found here. Insiders have sold 42,561 shares of company stock worth $ 23,557,413 over the last 90 days. Corporate insiders own 0.43% of the company stock.
About Thermo Fisher Scientific: (Get Rating)
Thermo Fisher Scientific Inc offers life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and service worldwide. The company Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.
Further Reading:
Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc. (NYSE: TMO – Get Rating).
Receive News & Ratings for Thermo Fisher Scientific Daily: – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Thermo Fisher Scientific and related companies with MarketBeat.com’s FREE daily email newsletter.
.